Note that this is the continuation of the joint phase 2, not one of the registration studies.
Generally positive. Adverse events were pretty much as expected, and did not visibly correlate with dose. Efficacy was as good as, but disappointingly not superior to, the anti-TNFs. Absolutely for sure, shingles vaccination before start of treatment should be on the label. I'm writing after one viewing of the presentation, but my impression was that anemia worsened modestly over time (not to a degree likely to limit treatment).